Unknown PHASE4 INTERVENTIONAL 4-arm NCT05969522

Stratified Therapy on Pediatric AAGN (STPARS)

Stratified Therapy on Pediatric AAGN Based on Risk Assessment-A Prospective, Multicenter, Open, Tendentious Matched Control Clinical Study

Sponsor: Wang Mo

Conditions ANCA-Associated Glomerulonephritis Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis

Interventions GlucoCorticoid

Updated 4 times since 2023 Last updated: Jul 23, 2023 Started: Jan 1, 2023 Primary completion: Dec 31, 2023 Completion: Dec 31, 2025

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT05969522, this PHASE4 trial focuses on ANCA-Associated Glomerulonephritis and Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis and remains ongoing. Sponsored by Wang Mo, it has been updated 4 times since 2023, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.

Status Flow

Change History

4 versions recorded

Feb 2026 — Present [monthly]

Unknown PHASE4

Status: Recruiting → Unknown
Sep 2024 — Feb 2026 [monthly]

Recruiting PHASE4
Jul 2024 — Sep 2024 [monthly]

Recruiting PHASE4
Sep 2023 — Jul 2024 [monthly]

Recruiting PHASE4

First recorded

Jan 2023

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Wang Mo

Data source: Children's Hospital of Chongqing Medical University

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Chongqing, China